Hirsch F R, Osterlind K, Hansen H H
Cancer. 1983 Dec 1;52(11):2144-50. doi: 10.1002/1097-0142(19831201)52:11<2144::aid-cncr2820521128>3.0.co;2-n.
Three hundred seventy-five consecutive patients treated with intensive chemotherapy in the same institution are included in this study in order to evaluate the prognostic significance of the World Health Organization's (WHO) subclassification of small cell lung cancer. Morphologic subtyping, based on primary biopsy specimens, was obtained in 200 patients. Oat cell type was diagnosed in 106 patients (53%), while intermediate subtype was diagnosed in 93 patients (47%), including 27 patients (14%) with small cell/large cell morphologic features. One patient had combined oat cell type. No difference in survival period was observed between the group of patients classified as oat cell versus the group with intermediate subtype. However, a significantly shorter survival period was demonstrated for patients with small cell/large cell features compared with patients with pure small cell carcinoma (median 168 days versus 280 days, P less than 0.01). It is concluded that there is no difference in survival period between patients with oat cell and intermediate subtype of small cell lung cancer using the criteria of the WHO. However, it might be of prognostic importance to identify patients with tumors demonstrating small cell/large cell features.
本研究纳入了在同一机构接受强化化疗的375例连续患者,以评估世界卫生组织(WHO)对小细胞肺癌的亚分类的预后意义。对200例患者的原发性活检标本进行了形态学亚型分类。106例患者(53%)被诊断为燕麦细胞型,93例患者(47%)被诊断为中间亚型,其中27例患者(14%)具有小细胞/大细胞形态特征。1例患者为混合型燕麦细胞型。燕麦细胞型患者组与中间亚型患者组之间未观察到生存期差异。然而,与纯小细胞癌患者相比,具有小细胞/大细胞特征的患者生存期明显缩短(中位生存期分别为168天和280天,P<0.01)。结论是,根据WHO的标准,燕麦细胞型和小细胞肺癌中间亚型患者的生存期无差异。然而,识别具有小细胞/大细胞特征肿瘤的患者可能具有预后重要性。